Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01178138 · ClinicalTrials.gov registry record · Phase 2
Monoamine Antagonist Therapies for Methamphetamine Abuse Prazosin
A Phase 2 study, sponsored by University of Arkansas.
- Completed
- Registry status
- Phase 2
- Development phase
- 24
- Enrollment target
NCT01178138 is a Phase 2 study that has completed, run by University of Arkansas. The registered enrollment target is 24 participants.
The verdict
NCT01178138, a Phase 2 study, has completed, sponsored by University of Arkansas.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 24 participants
- Enrollment target
Study Summary
This protocol will test the safety, effectiveness and the metabolism and action of prazosin as a potential therapy for methamphetamine abuse. This will be accomplished by performing a series of human laboratory studies. In each of these studies, the safety and effectiveness of the test medication (prazosin) in the treatment of methamphetamine effects will be determined. The study hypothesis is that prazosin will block the methamphetamine receptor function, reducing the reinforcing effects of central nervous system effects in humans.
Interventions
- DRUG Prazosin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2009-12 |
| Est. Completion | 2013-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01178138
The ClinicalTrials.gov registry entry for NCT01178138 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Arkansas, which has 318 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Prazosin is the first listed.
NCT01178138 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01178138 about?
NCT01178138 is a clinical study titled "Monoamine Antagonist Therapies for Methamphetamine Abuse Prazosin". This protocol will test the safety, effectiveness and the metabolism and action of prazosin as a potential therapy for methamphetamine abuse. This will be accomplished by performing a series of human laboratory studies. In each of these studies, the safety and effectiveness of the test medication (p...
What is the current status of trial NCT01178138?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 24 participants. The study started on 2009-12. Estimated completion is 2013-06.
What interventions are being tested in trial NCT01178138?
The interventions under investigation include: Prazosin (DRUG).
Who is sponsoring clinical trial NCT01178138?
This trial is sponsored by University of Arkansas, which has 318 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.